-
Ultimovacs ASA: Share capital increase related to exercise of options
-
Ultimovacs Starts Clinical Evaluation of Novel TET-Platform with Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine
-
Ultimovacs ASA: Fourth quarter 2020 result presentation
-
Ultimovacs ASA: Mandatory notification of trade by primary insiders
-
Ultimovacs ASA: Invitation to fourth quarter 2020 results webcast presentation
-
Ultimovacs ASA: Mandatory notification of trade by primary insider
-
Ultimovacs Announces NIPU Trial Design Poster Presented at World Conference of Lung Cancer Singapore 2020
-
Securities Regulation of 29 June 2007 (“STA”) – Disclosure of Significant Shareholding
-
Financial calendar
-
Ultimovacs ASA: Mandatory notification of trade by primary insider
